Compare DAO & ERAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DAO | ERAS |
|---|---|---|
| Founded | 2006 | 2018 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 927.7M |
| IPO Year | 2019 | 2021 |
| Metric | DAO | ERAS |
|---|---|---|
| Price | $8.84 | $3.49 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $3.71 |
| AVG Volume (30 Days) | 135.9K | ★ 2.0M |
| Earning Date | 11-20-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 155.59 | N/A |
| EPS | ★ 0.17 | N/A |
| Revenue | ★ $798,421,874.00 | N/A |
| Revenue This Year | $5.23 | N/A |
| Revenue Next Year | $13.46 | N/A |
| P/E Ratio | $53.98 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $6.30 | $1.01 |
| 52 Week High | $11.82 | $3.62 |
| Indicator | DAO | ERAS |
|---|---|---|
| Relative Strength Index (RSI) | 39.23 | 65.52 |
| Support Level | $8.81 | $3.15 |
| Resistance Level | $9.90 | $3.48 |
| Average True Range (ATR) | 0.44 | 0.24 |
| MACD | -0.04 | 0.02 |
| Stochastic Oscillator | 4.00 | 66.16 |
Youdao Inc develops and markets software applications. It engages in developing technologies to provide learning content, applications, and solutions. The firm operates in three segments: Learning services, Smart devices, and Online marketing services. The majority of its revenue comes from the Learning services segment, which generates revenues from online courses, mainly including Youdao Premium Courses, NetEase Cloud Classroom, and China University MOOC. The learning products segment includes sales of smart devices such as the Youdao Dictionary Pen and the Youdao Pocket Translator. Geographically, all of its revenue is generated from the People's Republic of China.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.